Widely anticipated drug for Alzheimer's fails to bring benefits

Eli Lilly have today announced that their Alzheimer's disease drug in development, Solanezumab, did not show benefit for people with mild Alzheimer's.
Source: Alzheimers Society - Category: Geriatrics Source Type: news
More News: Alzheimer's | Geriatrics